CVAC vs VTRS: fair value comparison
CureVac N.V. and Viatris Inc. · Updated 2026-10-19
CVAC reports in EUR, so no same-currency fair-value verdict is published for it. VTRS is still awaiting a full valuation verdict under our six-validated-windows standard. Within Healthcare, VTRS currently ranks higher by quality score.
| CVAC | VTRS | |
|---|---|---|
| Verdict | Awaiting full valuation | Awaiting full valuation |
| Last price | $4.66 | $17.64 |
| 12-month range | $4.12–$5.49 | $10.11–$18.66 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #142 of 301 Healthcare | #140 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | — | Moderate |
| Margin trend | Expanding | Contracting |
| Revenue growth | — | Declining |
| RSI zone | Overbought | Neutral |
| 50/200-day trend | Mixed | — |
| DCF cross-check | — | Overvalued |
| 52-week position | The lower-middle quarter | The top quarter |
Full single-stock breakdowns: CVAC fair value analysis · VTRS fair value analysis